Biomarkers of inflammation and hemostasis associated with left ventricular mass: The multiethnic study of atherosclerosis (MESA)

International Journal of Molecular Epidemiology and Genetics

Volumn 2, Issue 4, 2011, Pages 391-400

  Arnett, Donna K ^a   McClelland, Robyn L ^b   Bank, Alan ^c   Bluemke, David A ^d   Cushman, Mary ^e   Szalai, Alexander J ^f   Jain, Nishank ^a   Gomes, Antoinette S ^g   Heckbert, Susan R ^b   Gregory Hundley, W ^h   Lima, João A ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarker; Hemostasis; Inflammation; Left ventricle

Indexed keywords

BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR RECEPTOR 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CARDITIS; CLINICAL PROTOCOL; DEMOGRAPHY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; REGRESSION ANALYSIS; STANDARDIZATION;

EID: 83655181215     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Koren MJ, Mensah GA, Blake J, Laragh JH and Devereux RB. Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am J Hypertens 1993; 6: 815-823.
2. Ghali JK 3rd, Liao Y and Cooper RS. Left Ventricular Hypertrophy in the Elderly. Am J Geriatr Cardiol 1997; 6: 38-49.
3. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A and Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009; 52: 153-167.
4. Opie LH, Commerford PJ, Gersh BJ and Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367: 356-367.
5. Libby P, Ridker PM and Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
6. Conen D, Zeller A, Pfisterer M and Martina B. Usefulness of B-type natriuretic peptide and Creactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2006; 97: 249-252.
7. Leibowitz D, Planer D, Ben-Ivgi F, Weiss AT and Bursztyn M. Tumor necrosis factor and interleukin- 6 levels in hypertensive patients with and without left ventricular hypertrophy. Blood Press 2005; 14: 21-24.
8. Kutlay S, Dincer I, Sengul S, Nergizoglu G, Duman N and Erturk S. The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients. Am J Kidney Dis 2006; 47: 485-492.
9. Kim BS, Jeon DS, Shin MJ, Kim YO, Song HC, Lee SH, Kim SY, Choi EJ, Chang YS and Bang BK. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol 2005; 25: 189-195.
10. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G and Buemi M. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 2003; 33: 561-566.
11. Palmieri V, Celentano A, Roman MJ, de Simone G, Lewis MR, Best L, Lee ET, Robbins DC, Howard BV and Devereux RB. Fibrinogen and preclinical echocardiographic target organ damage: the strong heart study. Hypertension 2001; 38: 1068-1074.
12. Kurdi M, Randon J, Cerutti C and Bricca G. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem 2005; 269: 95-101.
13. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG and Mann DL. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 2004; 109: 262-268.
14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M and Tracy RP. Multiethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871-881.
15. Li AE, Kamel I, Rando F, Anderson M, Kumbasar B, Lima JA and Bluemke DA. Using MRI to assess aortic wall thickness in the multiethnic study of atherosclerosis: distribution by race, sex, and age. AJR Am J Roentgenol 2004; 182: 593-597.
16. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, Jerosch-Herold M, Pearson G, Sinha S, Arai A, Lima JA and Bluemke DA. Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. AJR Am J Roentgenol 2006; 186: S357-365.
17. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL and Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
18. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K and Ueda R. Circulating thrombomodulin levels are related to latent progression of atherosclerosis in hypertensive patients. Hypertens Res 2003; 26: 479-483.
19. Chambless LE, Heiss G, Shahar E, Earp MJ and Toole J. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2004; 160: 259-269.
20. Woodward M, Rumley A, Welsh P, MacMahon S and Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007; 5: 1795-1800.
21. Chen F, Eriksson P, Hansson GK, Herzfeld I, Klein M, Hansson LO and Valen G. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 2005; 15: 57-65.
22. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I and Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibodybased enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
23. Lutsey PL, Cushman M, Steffen LM, Green D, Barr RG, Herrington D, Ouyang P and Folsom AR. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 2006; 4: 2629-2635.
24. Nettleton JA, Steffen LM, Mayer-Davis EJ, Jenny NS, Jiang R, Herrington DM and Jacobs DR Jr. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2006; 83: 1369-1379.
25. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, Hundley WG, Lima JA and Bluemke DA. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 2006; 48: 2285-2292.
26. Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, de Lemos JA and Drazner MH. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension 2007; 49: 1385-1391.
27. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ and Vasan RS. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008; 118: 2252-2258, 2255p following 2258.
28. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S and Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factoralpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
29. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, de Caterina M, Leosco D, Vicario ML and Bonaduce D. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J 2000; 140: E28.
30. Raymond RJ, Dehmer GJ, Theoharides TC and Deliargyris EN. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 2001; 141: 435-438.
31. Orus J, Roig E, Perez-Villa F, Pare C, Azqueta M, Filella X, Heras M and Sanz G. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 2000; 19: 419-425.
32. Lip GY, Blann AD, Jones AF, Lip PL and Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566-1571.
33. Chong AY, Freestone B, Lim HS, Kistorp C, Gustafsson F, Hildebrandt P and Lip GY. Plasma von Willebrand factor and soluble Eselectin levels in stable outpatients with systolic heart failure: the Frederiksberg heart failure study. Int J Cardiol 2007; 119: 80-82.
34. Shai I, Pischon T, Hu FB, Ascherio A, Rifai N and Rimm EB. Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease. Obesity (Silver Spring) 2006; 14: 2099-2106.
35. Ferguson MA, Gutin B, Owens S, Litaker M, Tracy RP and Allison J. Fat distribution and hemostatic measures in obese children. Am J Clin Nutr 1998; 67: 1136-1140.
36. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M and Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC study. Atherosclerosis Risk in Communities. Obes Res 2000; 8: 279-286.
37. Malmqvist K, Wallen HN, Held C and Kahan T. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 2002; 20: 1563-1569.
38. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW and Vasan RS. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109: 2850-2856.